Holen Sie sich die Stockscreener-App
0.00
2.94%
-0.102
Schlusskurs vom Vortag:
$0.102
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.62M
KGV:
0.00
EPS:
-244.2719
Netto-Cashflow:
$-17.61M
1W Leistung:
-2.94%
1M Leistung:
-22.22%
6M Leistung:
-74.07%
1J Leistung:
+623.57%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.00
Neximmune Inc Stock (NEXI) Company Profile
Compare NEXI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEXI
Neximmune Inc
|
0.00 | 0 | 0 | -20.62M | -17.61M | -244.27 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neximmune Inc Stock (NEXI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-01 | Eingeleitet | Raymond James | Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-03-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Neximmune Inc Aktie (NEXI) Neueste Nachrichten
NexImmune, Inc. Revenue Breakdown – OTC:NEXI - TradingView
Neximmune Inc (NEXI) Peer Comparison – Compare with Others - valueresearchonline.com
NexImmune, Inc. Revenue Breakdown – LS:A3EUTV - TradingView
NexImmune stock trades on delisting news after business combination progress - Ad-hoc-news.de
Price to earnings forward of NexImmune, Inc. – OTC:NEXI - TradingView
Price to book forward of NexImmune, Inc. – OTC:NEXI - TradingView
Price to sales forward of NexImmune, Inc. – OTC:NEXI - TradingView
Enterprise value to revenue forward of NexImmune, Inc. – OTC:NEXI - TradingView
Enterprise value to EBIT forward of NexImmune, Inc. – OTC:NEXI - TradingView
NexImmune, Inc. Actuals & Estimates (LS:A3EUTV) - TradingView
Nextcom’s 2019 Omnibus Incentive Plan Amendment Approved: Key Shareholder Voting Results and Executive Compensation Insights – Minichart - Minichart
NexImmune StockSaturday deep dive into the immunotherapy micro-cap - AD HOC NEWS
Number of shareholders of NexImmune, Inc. – OTC:NEXI - TradingView
NexImmune Inc stock (US65343B1044): small-cap biotech pivots as it explores strategic options - AD HOC NEWS
NexImmune Inc stock (US65343B1044): what’s next after the reverse merger with MEI Pharma - AD HOC NEWS
NexImmune Inc stock (US65343B1044): Nasdaq delisting shifts focus to restructuring - AD HOC NEWS
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer - Bolsamania
NexImmune Inc stock (US65343B1044): Is its T-cell therapy platform strong enough to unlock biotech u - AD HOC NEWS
NexImmune Inc stock (US65343B1044): Is its T cell platform strong enough to unlock immunotherapy ups - AD HOC NEWS
NexImmune (NEXI) was downgraded to a Hold Rating at Citi - The Globe and Mail
ITRMF Stock Price and Chart — OTC:ITRMF - TradingView
Stock List: Research Stocks from Around the World - gurufocus.com
NexImmune Inc stock faces renewed scrutiny amid clinical trial updates and biotech sector volatility - AD HOC NEWS
NexImmune Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
NexImmune Inc Stock (ISIN: US65343B1044): Immunotherapy Play Eyes Clinic Expansion Amid Biotech Vola - AD HOC NEWS
NexImmune Inc Stock (ISIN: US65343B1044) Faces Volatility Amid Biotech Sector Pressures - AD HOC NEWS
Contrasting ASLAN Pharmaceuticals (NASDAQ:ASLN) & NexImmune (OTCMKTS:NEXI) - Defense World
NexImmune Inc Is Exploding Online – But Is NEXI Stock a Hidden Gem or a Total Trap? - AD HOC NEWS
The Truth About NexImmune Inc: Why Everyone Is Suddenly Watching This Micro-Cap Wildcard - AD HOC NEWS
NexImmune’s Vanishing Act: What Happens When a Ticker Survives but the Company Does Not? - AD HOC NEWS
NexImmune (NEXI) Short Interest & Short Float | Updated May 2026 - MarketBeat
NexImmune (NEXI) Stock Price, News & Analysis - MarketBeat
Eloxx Pharmaceut (ELOX) Stock Price, News & Analysis - Stock Titan
NEXI Stock Price, News & Analysis - Stock Titan
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Vanotech Appoints Matthew Schiller to Lead Business Development - citybiz
TRVN Stock Price and Chart — OTC:TRVN - TradingView
Neximmune Inc (NEXI) Stock Price and News - The Globe and Mail
Immunomodulators Market Size to Worth Around US$ 1,237.66 Bn by 2033 - BioSpace
NexImmune moves forward with wind-down process - bizjournals.com
NEXI S-8 POS & SEC FilingsYahoo Finance - Yahoo! Finance Canada
NexImmune shareholders approve company dissolution - Investing.com
NexImmune adjourns special meeting to explore options By Investing.com - Investing.com UK
NEXI Stock Price and Chart — OTC:NEXI - TradingView
NEXI Stock Alert: NexImmune Delists From Nasdaq - InvestorPlace
NexImmune Faces Nasdaq Delisting, Adjourns Shareholder Meeting - Investing.com
LSDIF Stock Price and Chart — OTC:LSDIF - TradingView
VAXX Stock Price and Chart — OTC:VAXX - TradingView
PBLA Stock Price and Chart — OTC:PBLA - TradingView
Zhengbin Yao Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Stock Titan
Finanzdaten der Neximmune Inc-Aktie (NEXI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
Kapitalisierung:
|
Volumen (24h):